Chemotherapy for Malignant Pleural Mesothelioma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-04-06

AUTHORS

Linda L Garland

ABSTRACT

Opinion statementAll MPM patients with a good performance status should be considered for enrollment on clinical trials. With that said, the standard frontline therapy for fit MPM patients remains an antifolate/platinum doublet, based on large, well powered randomized clinical trials that showed not only a survival benefit for antifolate/platinum regimens but also improvements in quality of life and/or symptoms. For less fit patients, single agents can be used as frontline therapy. In the second line setting, there is benefit from retreatment with single agent pemetrexed after prior exposure to that agent, as well as after exposure to other chemotherapeutic agents. Other single chemotherapy agents and combinations are viable options for fit patients who have had relatively long time to progression after their frontline therapy. Additionally, several prognostic scales designed for MPM (CALGB and EORTC) provide additional means to better select patients for frontline and second line chemotherapy. More... »

PAGES

181-188

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11864-011-0152-6

DOI

http://dx.doi.org/10.1007/s11864-011-0152-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1007072178

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21468683


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mesothelioma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pleural Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Precision Medicine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Arizona Cancer Center, Suite 1969H, 1515 N. Campbell Ave., 85724, Tucson, AZ, USA", 
          "id": "http://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA", 
            "Arizona Cancer Center, Suite 1969H, 1515 N. Campbell Ave., 85724, Tucson, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garland", 
        "givenName": "Linda L", 
        "id": "sg:person.01322145005.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322145005.35"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s12032-010-9553-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005827538", 
          "https://doi.org/10.1007/s12032-010-9553-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-04-06", 
    "datePublishedReg": "2011-04-06", 
    "description": "Opinion statementAll MPM patients with a good performance status should be considered for enrollment on clinical trials. With that said, the standard frontline therapy for fit MPM patients remains an antifolate/platinum doublet, based on large, well powered randomized clinical trials that showed not only a survival benefit for antifolate/platinum regimens but also improvements in quality of life and/or symptoms. For less fit patients, single agents can be used as frontline therapy. In the second line setting, there is benefit from retreatment with single agent pemetrexed after prior exposure to that agent, as well as after exposure to other chemotherapeutic agents. Other single chemotherapy agents and combinations are viable options for fit patients who have had relatively long time to progression after their frontline therapy. Additionally, several prognostic scales designed for MPM (CALGB and EORTC) provide additional means to better select patients for frontline and second line chemotherapy.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11864-011-0152-6", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1022080", 
        "issn": [
          "1527-2729", 
          "1534-6277"
        ], 
        "name": "Current Treatment Options in Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "keywords": [
      "frontline therapy", 
      "fit patients", 
      "MPM patients", 
      "clinical trials", 
      "single agent", 
      "standard frontline therapy", 
      "less fit patients", 
      "second-line chemotherapy", 
      "good performance status", 
      "randomized clinical trials", 
      "single chemotherapy agent", 
      "malignant pleural mesothelioma", 
      "quality of life", 
      "platinum doublets", 
      "line chemotherapy", 
      "performance status", 
      "survival benefit", 
      "platinum regimens", 
      "pleural mesothelioma", 
      "chemotherapy agents", 
      "prognostic scale", 
      "patients", 
      "chemotherapeutic agents", 
      "prior exposure", 
      "therapy", 
      "chemotherapy", 
      "second line", 
      "trials", 
      "agents", 
      "exposure", 
      "viable option", 
      "regimens", 
      "mesothelioma", 
      "retreatment", 
      "symptoms", 
      "progression", 
      "enrollment", 
      "additional means", 
      "benefits", 
      "status", 
      "options", 
      "frontline", 
      "MPM", 
      "long time", 
      "life", 
      "combination", 
      "quality", 
      "lines", 
      "time", 
      "scale", 
      "means", 
      "doublet", 
      "Opinion statementAll MPM patients", 
      "statementAll MPM patients", 
      "fit MPM patients", 
      "antifolate/platinum regimens"
    ], 
    "name": "Chemotherapy for Malignant Pleural Mesothelioma", 
    "pagination": "181-188", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1007072178"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11864-011-0152-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21468683"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11864-011-0152-6", 
      "https://app.dimensions.ai/details/publication/pub.1007072178"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_536.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11864-011-0152-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11864-011-0152-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11864-011-0152-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11864-011-0152-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11864-011-0152-6'


 

This table displays all metadata directly associated to this object as RDF triples.

147 TRIPLES      22 PREDICATES      89 URIs      80 LITERALS      13 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11864-011-0152-6 schema:about N04b75db325134f41ba17db03a65e66ee
2 N32af719d137b418bb05392ebe505e2c0
3 N881f27cdcda14da0975ccb34e79f8156
4 Nbfe50ce2825b45d4881015d5e354d5dd
5 Nd9741cb51cfa42508754b04b9e11b23d
6 Ne6c546ab099a440fa8cab1c4fe3c8d78
7 anzsrc-for:11
8 anzsrc-for:1112
9 schema:author Nd36a64889a0b474e9be387ec056cbbd1
10 schema:citation sg:pub.10.1007/s12032-010-9553-9
11 schema:datePublished 2011-04-06
12 schema:datePublishedReg 2011-04-06
13 schema:description Opinion statementAll MPM patients with a good performance status should be considered for enrollment on clinical trials. With that said, the standard frontline therapy for fit MPM patients remains an antifolate/platinum doublet, based on large, well powered randomized clinical trials that showed not only a survival benefit for antifolate/platinum regimens but also improvements in quality of life and/or symptoms. For less fit patients, single agents can be used as frontline therapy. In the second line setting, there is benefit from retreatment with single agent pemetrexed after prior exposure to that agent, as well as after exposure to other chemotherapeutic agents. Other single chemotherapy agents and combinations are viable options for fit patients who have had relatively long time to progression after their frontline therapy. Additionally, several prognostic scales designed for MPM (CALGB and EORTC) provide additional means to better select patients for frontline and second line chemotherapy.
14 schema:genre article
15 schema:inLanguage en
16 schema:isAccessibleForFree false
17 schema:isPartOf N0450255fbd50491e8579679e76884a16
18 N3df1f61cad2d459dbb93a88db304346e
19 sg:journal.1022080
20 schema:keywords MPM
21 MPM patients
22 Opinion statementAll MPM patients
23 additional means
24 agents
25 antifolate/platinum regimens
26 benefits
27 chemotherapeutic agents
28 chemotherapy
29 chemotherapy agents
30 clinical trials
31 combination
32 doublet
33 enrollment
34 exposure
35 fit MPM patients
36 fit patients
37 frontline
38 frontline therapy
39 good performance status
40 less fit patients
41 life
42 line chemotherapy
43 lines
44 long time
45 malignant pleural mesothelioma
46 means
47 mesothelioma
48 options
49 patients
50 performance status
51 platinum doublets
52 platinum regimens
53 pleural mesothelioma
54 prior exposure
55 prognostic scale
56 progression
57 quality
58 quality of life
59 randomized clinical trials
60 regimens
61 retreatment
62 scale
63 second line
64 second-line chemotherapy
65 single agent
66 single chemotherapy agent
67 standard frontline therapy
68 statementAll MPM patients
69 status
70 survival benefit
71 symptoms
72 therapy
73 time
74 trials
75 viable option
76 schema:name Chemotherapy for Malignant Pleural Mesothelioma
77 schema:pagination 181-188
78 schema:productId N3ec267c575854f598cdf1e03a80d2d9d
79 N7a497ca733bb493f865565c9f10c23e1
80 Nb040da27070649608784fb5bb5eb4e6d
81 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007072178
82 https://doi.org/10.1007/s11864-011-0152-6
83 schema:sdDatePublished 2022-01-01T18:24
84 schema:sdLicense https://scigraph.springernature.com/explorer/license/
85 schema:sdPublisher Na8ca074908964faca7374370187947e3
86 schema:url https://doi.org/10.1007/s11864-011-0152-6
87 sgo:license sg:explorer/license/
88 sgo:sdDataset articles
89 rdf:type schema:ScholarlyArticle
90 N0450255fbd50491e8579679e76884a16 schema:volumeNumber 12
91 rdf:type schema:PublicationVolume
92 N04b75db325134f41ba17db03a65e66ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Humans
94 rdf:type schema:DefinedTerm
95 N32af719d137b418bb05392ebe505e2c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Mesothelioma
97 rdf:type schema:DefinedTerm
98 N3df1f61cad2d459dbb93a88db304346e schema:issueNumber 2
99 rdf:type schema:PublicationIssue
100 N3ec267c575854f598cdf1e03a80d2d9d schema:name doi
101 schema:value 10.1007/s11864-011-0152-6
102 rdf:type schema:PropertyValue
103 N7a497ca733bb493f865565c9f10c23e1 schema:name dimensions_id
104 schema:value pub.1007072178
105 rdf:type schema:PropertyValue
106 N881f27cdcda14da0975ccb34e79f8156 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Precision Medicine
108 rdf:type schema:DefinedTerm
109 Na8ca074908964faca7374370187947e3 schema:name Springer Nature - SN SciGraph project
110 rdf:type schema:Organization
111 Nb040da27070649608784fb5bb5eb4e6d schema:name pubmed_id
112 schema:value 21468683
113 rdf:type schema:PropertyValue
114 Nbfe50ce2825b45d4881015d5e354d5dd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Antineoplastic Combined Chemotherapy Protocols
116 rdf:type schema:DefinedTerm
117 Nd36a64889a0b474e9be387ec056cbbd1 rdf:first sg:person.01322145005.35
118 rdf:rest rdf:nil
119 Nd9741cb51cfa42508754b04b9e11b23d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Antineoplastic Agents
121 rdf:type schema:DefinedTerm
122 Ne6c546ab099a440fa8cab1c4fe3c8d78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Pleural Neoplasms
124 rdf:type schema:DefinedTerm
125 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
126 schema:name Medical and Health Sciences
127 rdf:type schema:DefinedTerm
128 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
129 schema:name Oncology and Carcinogenesis
130 rdf:type schema:DefinedTerm
131 sg:journal.1022080 schema:issn 1527-2729
132 1534-6277
133 schema:name Current Treatment Options in Oncology
134 schema:publisher Springer Nature
135 rdf:type schema:Periodical
136 sg:person.01322145005.35 schema:affiliation grid-institutes:grid.134563.6
137 schema:familyName Garland
138 schema:givenName Linda L
139 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322145005.35
140 rdf:type schema:Person
141 sg:pub.10.1007/s12032-010-9553-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005827538
142 https://doi.org/10.1007/s12032-010-9553-9
143 rdf:type schema:CreativeWork
144 grid-institutes:grid.134563.6 schema:alternateName Arizona Cancer Center, Suite 1969H, 1515 N. Campbell Ave., 85724, Tucson, AZ, USA
145 schema:name Arizona Cancer Center, Suite 1969H, 1515 N. Campbell Ave., 85724, Tucson, AZ, USA
146 Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA
147 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...